Truist Securities Downgrades Terns Pharmaceuticals (TERN) to Hold

March 30, 2026 4:31 PM

Truist Securities analyst Srikripa Devarakonda downgraded Terns Pharmaceuticals (NASDAQ: TERN) from Buy to Hold with a price target of $53.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found